TrialJAMA oncology2020

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

Ciara M Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.